[go: up one dir, main page]

DK0621880T3 - Lægemiddelafgivelsessystem til samtidig afgivelse af lægemidler, der kan aktiveres af enzymer og lys - Google Patents

Lægemiddelafgivelsessystem til samtidig afgivelse af lægemidler, der kan aktiveres af enzymer og lys

Info

Publication number
DK0621880T3
DK0621880T3 DK93904633T DK93904633T DK0621880T3 DK 0621880 T3 DK0621880 T3 DK 0621880T3 DK 93904633 T DK93904633 T DK 93904633T DK 93904633 T DK93904633 T DK 93904633T DK 0621880 T3 DK0621880 T3 DK 0621880T3
Authority
DK
Denmark
Prior art keywords
drug
attached
copolymeric
carrier
anticancer
Prior art date
Application number
DK93904633T
Other languages
English (en)
Inventor
Jindrich Kopecek
Nancy Krinick
Original Assignee
Univ Utah
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Utah filed Critical Univ Utah
Application granted granted Critical
Publication of DK0621880T3 publication Critical patent/DK0621880T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/811—Peptides or proteins is immobilized on, or in, an inorganic carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815—Carrier is a synthetic polymer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815—Carrier is a synthetic polymer
    • Y10S530/816—Attached to the carrier via a bridging agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Processing Of Solid Wastes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK93904633T 1992-01-21 1993-01-21 Lægemiddelafgivelsessystem til samtidig afgivelse af lægemidler, der kan aktiveres af enzymer og lys DK0621880T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/822,924 US5258453A (en) 1992-01-21 1992-01-21 Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
PCT/US1993/000683 WO1993014142A1 (en) 1992-01-21 1993-01-21 Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light

Publications (1)

Publication Number Publication Date
DK0621880T3 true DK0621880T3 (da) 1999-12-20

Family

ID=25237341

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93904633T DK0621880T3 (da) 1992-01-21 1993-01-21 Lægemiddelafgivelsessystem til samtidig afgivelse af lægemidler, der kan aktiveres af enzymer og lys

Country Status (14)

Country Link
US (1) US5258453A (da)
EP (1) EP0621880B1 (da)
JP (1) JPH08500327A (da)
KR (1) KR100217186B1 (da)
AT (1) ATE184201T1 (da)
AU (1) AU663167B2 (da)
CA (1) CA2128330A1 (da)
DE (1) DE69326322T2 (da)
DK (1) DK0621880T3 (da)
FI (1) FI943430A7 (da)
HU (1) HUT68082A (da)
PL (1) PL172184B1 (da)
RU (1) RU94038047A (da)
WO (1) WO1993014142A1 (da)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543390A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5474765A (en) * 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
US5482719A (en) * 1992-10-30 1996-01-09 Guillet; James E. Drug delivery systems
US20040071637A1 (en) * 1993-04-27 2004-04-15 Elia James P. Method for repairing a damaged portion of a human organ
US5449720A (en) * 1993-05-24 1995-09-12 Biotech Australia Pty Limited Amplification of the VB12 uptake system using polymers
GB9320781D0 (en) * 1993-10-08 1993-12-01 Erba Carlo Spa Polymer-bound camptothecin derivatives
JP3315782B2 (ja) 1993-11-09 2002-08-19 理化学研究所 光化学反応による血液中抗癌剤変換装置
US5444650A (en) * 1994-01-25 1995-08-22 Nippondenso Co., Ltd. Semiconductor programmable read only memory device
US5599831A (en) * 1994-05-27 1997-02-04 Poretz; Ronald D. Method of preparation of pharmaceutical compositions
NO180167C (no) * 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
US6316007B1 (en) 1995-04-04 2001-11-13 Wound Healing Of Oklahoma Combined physical and immunotherapy for cancer
JP3929491B2 (ja) * 1995-04-04 2007-06-13 ウーンド・ヒーリング・オブ・オクラホマ・インコーポレーテッド イムノアジュバントを併用する光力学療法による癌治療
US5776925A (en) * 1996-01-25 1998-07-07 Pharmacyclics, Inc. Methods for cancer chemosensitization
US6375930B2 (en) 1996-06-04 2002-04-23 Board Of Regents, The University Of Texas System Membrane incorporation of texaphyrins
US6493570B1 (en) 1998-11-02 2002-12-10 Photogen, Inc. Method for improved imaging and photodynamic therapy
WO1999002139A1 (en) * 1997-07-10 1999-01-21 Keith Baker Methods for universally distributing therapeutic agents to the brain
US6251866B1 (en) 1997-08-05 2001-06-26 Watson Laboratories, Inc. Conjugates targeted to the interleukin-2 receptor
JP2003516305A (ja) * 1997-08-05 2003-05-13 ワトソン ファーマシューティカルズ， インコーポレイテッド インターロイキン−２レセプターに標的化された結合体
US8974363B2 (en) 1997-12-11 2015-03-10 Provectus Pharmatech, Inc. Topical medicaments and methods for photodynamic treatment of disease
CA2317549C (en) 1998-01-05 2006-04-11 University Of Washington Composition for enhancing transport through lipid-containing membranes, and uses thereof
US6087952A (en) * 1998-03-06 2000-07-11 Mobile Information Systems, Inc. Remote mobile data suite and method
US6223071B1 (en) 1998-05-01 2001-04-24 Dusa Pharmaceuticals Inc. Illuminator for photodynamic therapy and diagnosis which produces substantially uniform intensity visible light
US20030223978A1 (en) * 1998-05-22 2003-12-04 Nabi Ivan R. Conjugates of an AMF ligand and a cytotoxic molecule for use in cancer therapy
US8557298B2 (en) 1998-08-06 2013-10-15 Provectus Pharmatech, Inc. Medicaments for chemotherapeutic treatment of disease
US6986740B2 (en) * 1998-11-02 2006-01-17 Xantech Pharmaceuticals, Inc. Ultrasound contrast using halogenated xanthenes
US6222093B1 (en) * 1998-12-28 2001-04-24 Rosetta Inpharmatics, Inc. Methods for determining therapeutic index from gene expression profiles
US20030114366A1 (en) * 1999-01-11 2003-06-19 Francis J. Martin Microfabricated particles and method for treating solid tumors
GB9905911D0 (en) 1999-03-15 1999-05-05 Photocure As Method
AU1820400A (en) * 1999-11-17 2001-05-30 School Of Pharmacy, University Of London, The Conjugates of hpma copolymer and ellipticin
AU2764801A (en) * 2000-01-07 2001-07-24 University Of Washington Enhanced transport of agents using membrane disruptive agents
US6455073B1 (en) 2000-07-10 2002-09-24 Enzrel, Inc. Covalent microparticle-drug conjugates for biological targeting
US6454790B1 (en) * 2000-07-21 2002-09-24 Ceramoptec Industries, Inc. Treatment for Barrett's syndrome
HU229805B1 (en) 2000-11-29 2014-07-28 Pci Biotech As Photochemical internalization for delivery of molecules into the cytosol
AU2002216864A1 (en) * 2000-12-21 2002-07-01 Mcgill University Conjugates of antibodies and anticancer drugs
US7560424B2 (en) * 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
ES2300439T3 (es) * 2001-04-30 2008-06-16 Zystor Therapeutics , Inc. Reconocimiento subcelular de proteinas terapeuticas.
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
EP1401875A4 (en) * 2001-05-04 2005-01-26 Univ Utah Res Found HYALURONIC ACID-CONTAINING BIOKON JUGATES: TARGETED DELIVERY OF ANTIBODIES TO CANCER CELLS
AU2002332637A1 (en) * 2001-08-22 2003-03-10 Watson Pharmaceuticals, Inc. Conjugates targeted to target receptors
US20030072761A1 (en) * 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
WO2003051113A1 (en) 2001-12-14 2003-06-26 The University Of Wyoming Methods and compositions for controlled release of drugs
US6846311B2 (en) * 2002-04-02 2005-01-25 Acueity, Inc. Method and apparatus for in VIVO treatment of mammary ducts by light induced fluorescence
US20050169883A1 (en) * 2002-05-06 2005-08-04 Prestwich Glenn D. Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents
US7458982B2 (en) * 2002-10-04 2008-12-02 Photokinetix, Inc. Photokinetic delivery of biologically active substances using pulsed incoherent light
RU2256285C1 (ru) * 2003-10-14 2005-07-10 Закрытое акционерное общество "Электротекс" Способ плавного управления асинхронным электродвигателем с короткозамкнутым ротором
CN1922313B (zh) * 2004-02-10 2011-10-26 生物马林医药公司 酸性α-糖苷酶及其片段
HUE034923T2 (en) * 2004-03-31 2018-03-28 Univ Utah Res Found Macromolecular Dispensing Systems for Non-Invasive Imaging, Evaluation and Treatment of Arthritis and Other Inflammatory Diseases
US20070287680A1 (en) * 2004-05-10 2007-12-13 University Of Utah Research Foundation Combined Active and Passive Targeting of Biologically Active Agents
EP1888115A2 (en) * 2005-05-16 2008-02-20 Universite De Geneve Compounds for photochemotherapy
US20070299431A1 (en) * 2006-05-02 2007-12-27 Green Medical, Inc. Systems and methods for treating superficial venous malformations like spider veins
US7465312B2 (en) 2006-05-02 2008-12-16 Green Medical, Inc. Systems and methods for treating superficial venous malformations like spider veins
US20090326435A1 (en) * 2006-05-02 2009-12-31 Green Medical, Inc. Systems and methods for treating superficial venous malformations like varicose or spider veins
WO2007143209A2 (en) * 2006-06-02 2007-12-13 University Of Virginia Patent Foundation Luminescent diketonate polymers
US9150626B2 (en) 2006-06-02 2015-10-06 President And Fellows Of Harvard College Protein surface remodeling
GB0618524D0 (en) 2006-09-20 2006-11-01 Isis Innovation Multimeric particles
WO2008063511A2 (en) * 2006-11-13 2008-05-29 Zystor Therapeutics, Inc. Methods for treating pompe disease
HRP20170698T1 (hr) 2008-05-07 2017-09-22 Biomarin Pharmaceutical Inc. Lizosomski usmjereni peptidi i njihove uporabe
JP2012505228A (ja) * 2008-10-07 2012-03-01 レクサン ファーマシューティカルズ インコーポレイテッド Ｈｐｍａ−ドセタキセルまたはゲムシタビンコンジュゲートおよびその使用
KR20100083632A (ko) * 2009-01-14 2010-07-22 울산대학교 산학협력단 표적 단백질 분해효소 감응형 항암제 전구체
US9221886B2 (en) * 2009-04-28 2015-12-29 President And Fellows Of Harvard College Supercharged proteins for cell penetration
EP2475376B1 (en) 2009-06-17 2016-03-30 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
JP5749273B2 (ja) 2009-10-13 2015-07-15 レクサン ファーマシューティカルズ インコーポレイテッド 抗がん剤送達のためのポリマー系
US8492339B2 (en) * 2009-10-26 2013-07-23 Empire Technology Development Llc Angiogenesis promoted by caged growth factors
WO2011112482A2 (en) 2010-03-08 2011-09-15 University Of Utah Research Foundation Polymeric drug delivery conjugates and methods of making and using thereof
EP2576638B1 (en) 2010-05-25 2020-12-23 Syndevrx, Inc. Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
US8883503B2 (en) 2011-06-23 2014-11-11 Indian Institute Of Technology Kanpur Hydrogel scaffolds for tissue engineering
PT2774625T (pt) * 2011-09-05 2017-06-22 Maeda Hiroshi Sonda molecular fluorescente do tipo polímero
JP6180436B2 (ja) 2012-01-20 2017-08-16 イミュノフォトニクス，インコーポレーテッド キトサン由来組成物
US11773188B2 (en) 2012-01-20 2023-10-03 Immunophotonics, Inc Chitosan-derived compositions
BR112015025892A2 (pt) 2013-04-10 2017-07-25 Syndevrx Inc inibidores de metap2 e métodos para tratar obesidade
US20190002594A1 (en) 2014-07-16 2019-01-03 Immunophotonics, Inc. Chitosan-Derived Compositions
DK3386956T3 (da) 2015-12-10 2021-10-11 Syndevrx Inc Fumagillolderivater og polymorfer deraf
CA3239447A1 (en) 2016-01-11 2017-07-20 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction
AU2017283653C1 (en) 2016-06-16 2022-05-05 Oncoselect Therapeutics, Llc Porphyrin compounds and compositions useful for treating cancer
AU2018255269B2 (en) 2017-04-17 2023-03-09 The University Of Chicago Polymer materials for delivery of short-chain fatty acids to the intestine for applications in human health and treatment of disease
JP6894747B2 (ja) * 2017-04-19 2021-06-30 キヤノン株式会社 重合体
CA3117666A1 (en) 2018-10-26 2020-04-30 Syndevrx, Inc. Biomarkers of metap2 inhibitors and applications thereof
WO2021076865A1 (en) 2019-10-18 2021-04-22 University Of Utah Research Foundation Polymeric drug delivery conjugates and methods of making and using thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0103184B1 (en) * 1982-08-12 1990-01-17 Kanegafuchi Chemical Industry Co., Ltd. Activation of biocompatible terpolymers with biologicals whose binding complements are pathological effectors
GB8500209D0 (en) * 1985-01-04 1985-02-13 Ceskoslovenska Akademie Ved Synthetic polymeric drugs
EP0213811A3 (en) * 1985-08-16 1987-09-09 Johnson Matthey, Inc., Bateriocin-targeted compounds for cancer therapy

Also Published As

Publication number Publication date
HUT68082A (en) 1995-05-29
ATE184201T1 (de) 1999-09-15
FI943430A7 (fi) 1994-09-20
AU3593093A (en) 1993-08-03
CA2128330A1 (en) 1993-07-22
WO1993014142A1 (en) 1993-07-22
EP0621880A4 (en) 1995-04-19
DE69326322D1 (de) 1999-10-14
AU663167B2 (en) 1995-09-28
KR100217186B1 (ko) 1999-09-01
RU94038047A (ru) 1996-06-10
HU9402142D0 (en) 1994-09-28
FI943430A0 (fi) 1994-07-20
JPH08500327A (ja) 1996-01-16
EP0621880A1 (en) 1994-11-02
DE69326322T2 (de) 2000-02-17
EP0621880B1 (en) 1999-09-08
PL172184B1 (pl) 1997-08-29
US5258453A (en) 1993-11-02

Similar Documents

Publication Publication Date Title
DK0621880T3 (da) Lægemiddelafgivelsessystem til samtidig afgivelse af lægemidler, der kan aktiveres af enzymer og lys
Kopeček et al. Water soluble polymers in tumor targeted delivery
DE68918860D1 (de) Photoempfindliche mittel.
PT1028753E (pt) Libertacao de moleculas de poli(etilenoglicol)-conjugado a partir de hidrogeles degradaveis
FI942878A0 (fi) Pyrofeoforbideja ja niiden käyttö valovaikutushoidossa
CA2046916A1 (en) Methods and compositions for treatment of cancer using oligonucleotides
BRPI0416028B8 (pt) composto, conjugados do composto, composição farmacêutica e usos do conjugado
CO5180590A1 (es) Derivados de camptotecina que tienen actividad anti tumores
DK1137436T3 (da) Stimulering af T-celler mod selvantigener under anvendelse af CTLA-4-blokeringsmidler
EP0933995B8 (en) Method of treating endothelial injury
DE60032633D1 (de) Cytotoxische wirkstoffe enthaltend taxane und deren therapeutische anwendung
WO1997029779A3 (en) EGF-Genistein conjugates for the treatment of cancer
MXPA02006220A (es) Derivados carbamato de poli(etilenglicol) hidroliticamente degradables.
WO1998029105A3 (en) Method of treating prostatic diseases using delayed and/or sustained release vitamin d formulations
WO1999048536A3 (en) Delivery of long lasting therapeutic agents by forming covalent attachments in vivo
TR200001147T2 (tr) Kanser ve makular dejenerasyonun tedavisi için makrolidlerin kullanımı
BR9909087A (pt) Formulações para proteção de conjugados peg-alfa interferon
Duncan et al. Drug targeting in cancer therapy: the magic bullet, what next?
ES2376739T3 (es) Administración conjunta de un polisacárido con un agente quimioterapéutico para el tratamiento del cáncer
EP0838224A3 (en) Polymer-drug conjugates with an enzyme cleavable linker
TR199801732T2 (xx) Yeni taksoitler, bunlar�n haz�rlanmalar� ve ila� bile�imleri.
Říhová et al. Targetable photoactivalable drugs. 3. In vitro efficacy of polymer bound chlorin e6 toward human hepatocarcinoma cell line (PLC/PRF/5) targeted with galactosamine and to mouse splenocytes targeted with anti-Thy 1.2 antibodies
BR0014135A (pt) Composição farmacêutica fotoativável para destruição e/ou inaticação seletivas de células imunologicamente reativas, uso da mesma, e, métodos para prevenção de doença de enxerto-versus-hospedeiro associada com transplante alogênico de células tronco em um paciente, para tratamento de distúrbio imunológico em um paciente e para avaliar o mecanismo de transporte de células imunes e/ou malignas
CN104910277B (zh) 新型人源化抗cd22抗体-单甲基阿里他汀e偶联物及其制备方法
SE8601563D0 (sv) Matrismaterial, forfarande for framstellning derav och anvendning derav